CD274 and non-small cell lung carcinoma: The phase II PEMBRO-RT trial revealed that stereotactic body radiotherapy (SBRT) combined with pembrolizumab doubled objective response rates in PD-L1-negative NSCLC compared to immunotherapy alone (9).